<DOC>
	<DOC>NCT02423226</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of CT guided 125I seeds implant plus systemic chemotherapy for locally recurrent rectum cancer.</brief_summary>
	<brief_title>Computed Tomography-guided Brachytherapy Plus Chemotherapy for Locally Recurrent Rectum Cancer</brief_title>
	<detailed_description>The primary aim of this study is to determined the safety and efficacy of CT guided 125I seeds implant plus systemic chemotherapy for locally recurrent rectum cancer.The patients with recurrence in pelvic or on pelvic wall after rectal resection were treated with 125I seeds implant plus chemotherapy or chemotherapy alone. The side-effect, tumor response and survival data were recorded.</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<criteria>Limited locoregional recurrence including solitary recurrence at primary tumor bed, solitary intraabdominal peritoneal recurrence, and single regional lymph node recurrence (no more than 3 lymph nodes) based on diagnosis by CT, and confirmed by percutaneous puncture biopsy Secondline treatment for advanced colorectal cancer,irinotecan was not previously used. Age range 1870 years old ECOG performance status 01 Life expectancy of more than 3 months Adequate organ function Previous serious cardiac disease History of other malignancies except cured basal cell carcinoma of skin and carcinoma insitu of uterine cervix Pregnant or lactating women Chronic inflammatory bowel disease or intestinal obstruction Serious uncontrolled diseases and intercurrent infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>